 Massachusetts company had 80 employees and a handful of drug leads sourced from a machine learning platform that it boasted could speed up drug discovery timelines. Now with nearly 700 million in financing the company employs over 280 staff and plans to soon file an application for a second experimental drug to enter clinical trials in Europe said the CEO